← Human Trials & Peer-Reviewed Studies
Efficacy and safety of standardized lime peel supplement in adults with sleep disturbance: A randomized, double-blind, placebo-controlled, polysomnographic study.
Plain-language guide to PMID 39970858 (2025): double-blind randomized controlled trial of Copper (Supplement) in 80 subjects.
Key Facts
- PMID
- 39970858
- Journal
- Phytomedicine : international journal of phytotherapy and phytopharmacology
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Kim S et al. (10 authors)
- DOI
- 10.1016/j.phymed.2025.156510
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Copper (Supplement), published as a randomized controlled trial.
This study aimed to evaluate the effects of SLPS in adults experiencing sleep disturbances.
Why It Was Studied
Citrus peels are rich in flavonoids with potential sedative-hypnotic effects; however, these effects have not yet been fully explored.
Who Took Part
The abstract describes 80 subjects taking part.
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.
Neither the subjects nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.
What Was Measured
The subject headings attached to it are Polysomnography, Sleep Wake Disorders, Dietary Supplements, Citrus, Plant Extracts, Sleep and Hypnotics and Sedatives.
Author keywords: Citrus peels, Insomnia, Sedative-hypnotics, Sleep latency and Standardized lime peel supplement.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 80 subjects.
Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2025 (Phytomedicine : international journal of phytotherapy and phytopharmacology), a journal based in Germany.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.